Report overview
This report contains market size and forecasts of Human Insulin Regular in global, including the following market information:
Global Human Insulin Regular Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global Human Insulin Regular Market Sales, 2018-2023, 2023-2030, (Tons)
Global top five Human Insulin Regular companies in 2022 (%)
The global Human Insulin Regular market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Insulin Glargine Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Human Insulin Regular include Gan & Lee Pharmaceuticals, Bioton, Novo Nordisk, Tonghua Dongbao Pharmaceutical, Shenzhen Kexing Pharmaceutical, Zhuhai United Laboratories, Wanbang Biopharmaceuticals and Eli Lilly and Company, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Human Insulin Regular manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Insulin Regular Market, by Type, 2018-2023, 2023-2030 ($ Millions) & (Tons)
Global Human Insulin Regular Market Segment Percentages, by Type, 2022 (%)
Insulin Glargine
Recombinant Insulin Glargine
Global Human Insulin Regular Market, by Application, 2018-2023, 2023-2030 ($ Millions) & (Tons)
Global Human Insulin Regular Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Global Human Insulin Regular Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions) & (Tons)
Global Human Insulin Regular Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Insulin Regular revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Human Insulin Regular revenues share in global market, 2022 (%)
Key companies Human Insulin Regular sales in global market, 2018-2023 (Estimated), (Tons)
Key companies Human Insulin Regular sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Gan & Lee Pharmaceuticals
Bioton
Novo Nordisk
Tonghua Dongbao Pharmaceutical
Shenzhen Kexing Pharmaceutical
Zhuhai United Laboratories
Wanbang Biopharmaceuticals
Eli Lilly and Company
